ASND Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: The Motley Fool - Mentions: DYN BCRX ACAD RY ...

Why Dyne Therapeutics Stock Was Crushing it This Week

5 days ago - By: Ascendis Pharma

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

9 days ago - By: The Motley Fool

Ascendis (ASND) Q3 2025 Earnings Call Transcript

10 days ago - By: Ascendis Pharma

Ascendis Pharma Reports Third Quarter 2025 Financial Results

10 days ago - By: Zacks Investment Research - Mentions: MDT VEEV ACOG

MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth

11 days ago - By: Benzinga

A Look Ahead: Ascendis Pharma's Earnings Forecast

24 days ago - By: Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

12 days ago - By: Zacks Investment Research - Mentions: AUTL IMRX ANRO

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

15 days ago - By: Ascendis Pharma

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

17 days ago - By: Ascendis Pharma

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

19 days ago - By: Ascendis Pharma

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

a month ago - By: Ascendis Pharma

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

3 months ago - By: Ascendis Pharma

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

3 months ago - By: Ascendis Pharma

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

4 months ago - By: Ascendis Pharma

Ascendis Pharma Reports Second Quarter 2025 Financial Results

4 months ago - By: Ascendis Pharma

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

4 months ago - By: Yahoo Finance

Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment

4 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade

4 months ago - By: Ascendis Pharma

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

4 months ago - By: Yahoo Finance - Mentions: MS BMRN

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside

5 months ago - By: Ascendis Pharma

ASCENDIS PHARMA A/S - ADR (ASND) Stock News

ASND Latest News, Press Relases and Analysis

Why Dyne Therapeutics Stock Was Crushing it This Week

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Ascendis (ASND) Q3 2025 Earnings Call Transcript

Ascendis Pharma Reports Third Quarter 2025 Financial Results

MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth

A Look Ahead: Ascendis Pharma's Earnings Forecast

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025